Review anchor
Signal transducer and activator of transcription 5A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Signal transducer and activator of transcription 5A
CHEMBL5403
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Signal transducer and activator of transcription 5A as ChEMBL target CHEMBL5403, mapped to UniProt P42229. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5403
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P42229
Signal transducer and activator of transcription 5A
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Signal transducer and activator of transcription 5A matters
Signal transducer and activator of transcription 5A is reviewed as Signal transducer and activator of transcription 5A (UniProt P42229); the current evidence base includes 1 approved drug, 193 compounds, and 159 assays, with lead potency reaching pChEMBL 8.3.
Protein context
Signal transducer and activator of transcription 5A
Signal transducer and activator of transcription 5A Sequence length is 794 aa.
Review this target as Signal transducer and activator of transcription 5A, mapped to UniProt P42229. Sequence length is 794 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P42229
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 193 compounds, and 159 assays for this target. The dominant activity type is IC50. CHEMBL574058 is the current potency anchor at pChEMBL 8.3.
Use CHEMBL574058 as the tractability anchor when discussing potency (pChEMBL 8.3).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 8.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Signal transducer and activator of transcription 5A matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P42229, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
193
Total Compounds
159
Total Assays
1
Approved Drugs
IC50: 29.0, KI: 28.0, EC50: 1.0, KD: 2.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL574058
|
8.3 | IC50 | — |
|
|
No preferred name
CHEMBL603469
|
8.0 | IC50 | Clinical |
|
|
No preferred name
CHEMBL1231124
|
7.6 | IC50 | Clinical |
|
|
No preferred name
CHEMBL5397297
|
7.4 | EC50 | — |
|
|
No preferred name
CHEMBL5954872
|
7.4 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MOMELOTINIB
CHEMBL1078178
|
2023 |
Source Header